By acquiring T3 Pharma, a leader in bacterial cancer treatment, Boehringer Ingelheim broadens its offering in immunooncology.

Published Date: 27 Nov 2023

Germany: T3 Pharmaceuticals AG, a privately held clinical stage Swiss biotech company, has been acquired by Boehringer Ingelheim for an $.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Most NMIBC Recurrences Seen in BCG-Exposed Patients

2.

Ivonescimab Tops Pembrolizumab in PD-L1-Positive, Advanced NSCLC

3.

Novel radiotracer identifies biomarker for triple-negative breast cancer

4.

The standard for high-risk prostate cancer is supported by a study using high-dose RT and long-term ADT.

5.

Accuracy of Skin Cancer Diagnosis Varies by Physician, Exam Method


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot